Biomagnetics accepts Los Alamos National Labs' optical biosensor for disease diagnosis

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis. This new type of diagnostic device was developed in conjunction with the scientists and engineers at Los Alamos National Laboratory. The Company now plans to proceed with the process of ministration and commercialization of this groundbreaking technology.

Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. commented, "Today, the integrated optic biosensor moves out of the theoretical world of the laboratory into our possession. It is amazing that a device with such wide scale capabilities has been developed and delivered to our company. An integrated optical biosensor device holds the promise to allow relatively untrained medical personnel to diagnose a variety of diseases in a matter of only a few minutes. We will be proceeding with our plans to reengineer the technology into a format that can be utilized for clinical trials and commercialization later this year."